Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00665093

Enrollment

1569

Registered

2008-04-23

Start date

2007-05-31

Completion date

2008-01-31

Last updated

2017-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.

Interventions

DRUGbiphasic insulin aspart 30

Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation

DRUGinsulin detemir

Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Levemir® above 6 yrs * NovoMix® 30 above 18 yrs * Patients with Type 1 or Type 2 diabetes, including newly diagnosed

Exclusion criteria

* Current treatment with NovoMix® 30 or Levemir®

Design outcomes

Primary

Measure	Time frame
HbA1c	at 24 weeks

Secondary

Measure	Time frame
FPG, PG profile, weight, % of subjects on target	at 24 weeks

Countries

North Macedonia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026